GMP meets GCP
Management, Supply and Quality Assurance of Clinical Trials

3 – 5 November 2020, Barcelona, Spain

Highlights

- Rules and Regulations
  - Applicable legislation and GMP/GCP interfaces
  - Duties and responsibilities
  - Data Integrity
  - Typical inspection findings
- Supply Management
  - Packaging, labelling, distribution
  - Shelf-life extensions
  - Handling of comparators
  - GMP requirements at the investigational site
  - Trials outside the EU
- Study Management
  - Key tasks and responsibilities
  - The role of the hospital pharmacy
  - IMP-related documentation
- The Role of the QP in Clinical Trials
  - When does the QP responsibility end?
  - Oversight of the supply chain
- International Contracts and Agreements
- Workshops and Case Studies
Objective

During this course, well-experienced specialists will share their expert knowledge about important aspects of IMP Supplies and the Management of Clinical Trials. Hear essential aspects about the organisation and management of the supplies, their distribution, things to consider during the study and learn how the various regulations lead the way. During this event, the important interfaces between GMP and GCP will be elaborated.

Background

In the development of new pharmaceutical products, it is a challenge to design and initiate sound and appropriate studies. Compliance with GMP and GCP regulations is mandatory. A prerequisite for a successful study is the thorough planning of the clinical trial supplies. Beginning with the order, the manufacturing and supply of the IMPs, an efficient study management and full compliance with applicable rules and regulation will lead to satisfactory results. GMP and GCP requirements need to be considered and understood from all parties involved.

Trials outside the EU and contracts and agreements are two other aspects which require particular attention. Especially, in regard of trials performed in UK after the Brexit.

This course has been designed by the ECA to enhance and broaden your knowledge and to consolidate the various aspects which need to be taken into account for an efficient management of clinical trials.

Target Audience

Specialists, managers and executives from R&D dealing with the various aspects of IMP supply and clinical trial management. It addresses representatives from IMP manufacturing, packaging, QP certification and supply as well as from the study design and management and the respective Quality Assurance units. It is also directed to CROs and members of inspectorates and authorities.

Programme

Case Studies

- How things can go wrong
- Interface between GMP and GCP
- Clinical trials Phase I – III, Investigator-Initiated Trials and Pre-Approval Access to IMPs

Changes in the Regulatory Landscape of Clinical Trials

- GMP relevant Changes (including ICH E6(R2))
- Current status of the implementation progress of EMA’s Portal and Data base

CTS Planning

- Supply Chain Planning
- Comparators: selection, procurement, pedigree
- Blinding
- NIMPs
- Shelf-life assignment
- Outsourcing
- IRT: Pros and Cons to use for a particular study

Packaging and Labelling of IMPs

- Blinding aspects in packaging
- Packaging technology
- Unblinding risks during packaging
- Just-in-time labelling
- Relabeling
- Reconstitution

Data (and Study) Integrity in Clinical Trials

- Responsibilities of investigator, sponsor and monitor
- Vendors and contractors of electronic systems: Considerations and pitfalls
- Why do we need an Audit Trail (Review)?
- Inspection findings

GCP/GMP Inspections

- The inspection and monitoring process
- Typical and recurrent compliance issues
- Typical issues at the interfaces
- Inspections in Europe and beyond

Distribution of IMP Supplies

- Distribution concept and prerequisites
- IRT
- Temperature controlled shipments
- Temperature deviations
- Site transfer
- Depots
- Customs

GCP Aspects to Consider for IMPs

- Roles and responsibilities: Sponsor, CRA, Investigator
- ICH GCP
- Storage of IMPs
- Reconstitution
- Accountability and Reconciliation
- Sponsor: Achieving and Maintaining the Blind
- IMP return and destruction
- IMP related documentation
The Role of the QP in Clinical Trials

- When does the QP responsibility end?
- Dealing with deviations during distribution
- How to handle deviations at investigator sites
- Extension of shelf-life
- Oversight of distribution and transport
- The responsibility for comparators

Three Workshops on Case Studies

Evaluate and discuss with the other delegates and the speakers case studies on:

1. Study Planning:
   Challenges from a CTS coordinators perspective
2. Case Studies:
   Open Discussion of QP Tasks and Challenges in Clinical Trials
3. GCP Aspects:
   Handling IMPs at the Investigator’s Site

You will be able to attend all 3 workshops.

Handling IMPs at a Hospital Pharmacy

- The role of the hospital pharmacy: manufacturing, organisation, consultancy
- The interface of manufacturing IMPs at a hospital pharmacy and the daily work
- Investigator-Initiated Trials (IITs)
- FAQs: things you need to consider
- Challenges and problem solving

Contracts and Agreements in the Management of Clinical Trials

- Applicable law and jurisdiction
- Contractual partners and QP participation
- Contract concepts
- Typical building blocks

A last Case Study - how things can go wrong

- How would you have reacted?

Speakers

Inge De Meyer, Janssen Pharmaceutica NV (part of Johnson & Johnson), Belgium
Inge De Meyer is Manager QA of the Clinical Supply Chain and delegate QP. She is releasing IMPs for J&J sponsored clinical trials globally. In her role, she is also first point of contact for New Product Introduction and concomitant release activities.

Rita Hattemer-Apostel, Verdandi AG, Switzerland
Rita Hattemer-Apostel is founder and CEO of Verdandi AG, an independent Quality Management Consultancy for GCP/QA. She has worked in Pharma and CRO industry and has 18+ years of clinical QA experience. She has been President of SPAQA, the Swiss Professional Association of Quality Assurance (2003-2009) and Editor-in-Chief of the Quality Assurance Journal (2001-2011).

Dr Gundula Born, Germany
Dr Gundula Born is a pharmacist and Qualified Person (QP), with a more than 20 years track record in the pharmaceutical industry. She has filled roles in quality control and quality assurance. Her QP responsibilities cover both commercial and investigational medicinal products.

Dr Claudio Lorck, Abbvie Deutschland GmbH, Germany
Claudio Lorck is QP Lead for Clinical Product Supply EU. Before that he was Head of the Business Unit ‘Clinical Trial Materials’ and Qualified Person (QP) at Temmler. He started his career in Pharmaceutical Development, and became Quality Control Manager at Klinge Pharma. Later he was Quality Manager R&D and QP for IMPs at Fujisawa and Head of Clinical Trial Materials and QP at Astellas.

Dr Lenka Taylor, Pharmacy of the University Hospital Heidelberg, Germany
Dr Lenka Taylor is a Pharmacist, working at the Clinical Trial Department within the Pharmacy of the University Hospital Heidelberg. She is managing clinical trials within InPhaSol, the production unit of the University Hospital in Heidelberg, as well as commercial clinical studies. Within InPhaSol, Dr Taylor is appointed Head of Quality Control. She is also lecturer at the University of Freiburg (Pharmacy).

Mandy Budwal-Jagait (invited), Senior GCP Inspector, MHRA, UK
Mandy Budwal-Jagait is a Senior GCP inspector with the MHRA (Medicines and Healthcare products Regulatory Agency) and joined the Agency in April 2014. Mandy conducts a variety of GCP inspections in commercial and non-commercial organizations. Prior to joining the Agency, Mandy has held Clinical Research and Quality Assurance roles in the Pharmaceutical Industry.

Sandra Blim, AbbVie Deutschland GmbH, Germany
Sandra Blim studied pharmacy at the Johannes-Gutenberg-University in Mainz and joined AbbVie Deutschland GmbH in 2012 as Qualified Person (QP) Trainee in R&D Quality Assurance. From 2014 to 2018 Sandra was responsible as QP in R&D QA. Since 2018 she is Head of Production for IMP Packaging/Labelling.
If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
   - Cancellation until 2 weeks prior to the conference 10%,
   - Cancellation until 1 week prior to the conference 50%,
   - Cancellation within 1 week prior to the conference 100%.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012). German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.